Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Hold Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a research report sent to investors on Monday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Separately, Cantor Fitzgerald boosted their price objective on shares of Vanda Pharmaceuticals from $11.00 to $13.00 and gave the company an overweight rating in a report on Thursday, August 1st.

Vanda Pharmaceuticals Stock Performance

Shares of VNDA stock opened at $5.31 on Monday. The company has a market capitalization of $309.52 million, a price-to-earnings ratio of -66.38 and a beta of 0.75. Vanda Pharmaceuticals has a 52 week low of $3.30 and a 52 week high of $6.75. The company has a 50-day simple moving average of $5.79 and a 200 day simple moving average of $4.88.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.12). The business had revenue of $47.46 million during the quarter, compared to the consensus estimate of $48.50 million. Vanda Pharmaceuticals had a negative net margin of 6.00% and a negative return on equity of 2.01%. Sell-side analysts forecast that Vanda Pharmaceuticals will post -0.49 EPS for the current year.

Institutional Trading of Vanda Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in VNDA. Raymond James & Associates bought a new stake in shares of Vanda Pharmaceuticals during the 4th quarter worth approximately $42,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Vanda Pharmaceuticals by 352.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,658 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 5,186 shares during the period. Mackenzie Financial Corp bought a new stake in shares of Vanda Pharmaceuticals during the 4th quarter worth approximately $46,000. Bailard Inc. bought a new stake in shares of Vanda Pharmaceuticals during the 4th quarter worth approximately $111,000. Finally, Pinnacle Wealth Planning Services Inc. bought a new stake in shares of Vanda Pharmaceuticals during the 4th quarter worth approximately $87,000. Institutional investors own 88.14% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.